Insignis Therapeutics, Inc.
- | Biotech or pharma, therapeutic R&D
Insignis Therapeutics is a clinical stage pharmaceutical company developing a groundbreaking needle-free epinephrine sublingual spray, OSEPI (IN-001), which has the potential to transform the treatment of severe allergic reactions including anaphylaxis. FDA granted OSEPI Fast Track Designation status in July 2024.
Address
North HavenConnecticut
United States
)
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
)
){kind=logo}
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}